Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SCD | O00767 | 5/20 | 0.40 |
| ▸ | KCNJ1 | P48048 | 2/20 | 0.39 |
| ▸ | CXCR4 | P61073 | 3/20 | 0.38 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.38 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.38 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.38 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.38 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.38 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.38 |
| ▸ | KDM5C | P41229 | 1/20 | 0.38 |
| ▸ | KDM4C | Q9H3R0 | 1/20 | 0.38 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.36 |
| ▸ | PRMT5 | O14744 | 1/20 | 0.35 |
| ▸ | BPTF | Q12830 | 2/20 | 0.35 |
| ▸ | GPR4 | P46093 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18291567 | 0.78 | CXCR4 (0.46) | CXCR4CYP1A2KDM5CKDM4CLMNA | |
| SCHEMBL21850877 | 0.78 | LMNA (0.43) | SCDKCNJ1CXCR4CYP1A2LMNA | |
| SCHEMBL20168708 | 0.76 | KCNJ1 (0.43) | SCDKCNJ1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL21850829 | 0.73 | LMNA (0.43) | KCNJ1CXCR4CYP1A2KDM5CKDM4C | |
| SCHEMBL22199095 | 0.71 | SCD (0.48) | SCDKCNJ1CYP1A2CYP3A4CYP2D6 | |
| SCHEMBL21850871 | 0.71 | KCNJ1 (0.49) | KCNJ1CXCR4LMNASIGMAR1 | |
| SCHEMBL24135343 | 0.70 | CXCR4 (0.46) | CXCR4CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL24135549 | 0.70 | CYP2E1 (0.40) | CXCR4CYP1A2CYP3A4CYP2D6CYP19A1 | |
| SCHEMBL18291540 | 0.69 | CXCR4 (0.46) | CXCR4KDM5CKDM4CLMNASIGMAR1 | |
| SCHEMBL20037955 | 0.69 | CXCR4 (0.46) | CXCR4KDM5CKDM4CLMNASIGMAR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | BRISTOL MYERS SQUIBB CO (US) | 2020-04-09 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200109135-A1 | SUBSTITUTED NITROGEN CONTAINING COMPOUNDS | NR0B1, GRK1, GRIN1 | SCD 3634/4885KCNJ1 562/4885CXCR4 666/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.